Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA Margin (2021)

Atea Pharmaceuticals (AVIR) has 1 years of EBITDA Margin data on record, last reported at 60.95% in Q4 2021.

  • For Q4 2021, EBITDA Margin changed N/A year-over-year to 60.95%; the TTM value through Sep 2022 reached 18.11%, down 566.0%, while the annual FY2021 figure was 34.49%, 5700.0% up from the prior year.
  • EBITDA Margin reached 60.95% in Q4 2021 per AVIR's latest filing, up from 67.5% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 60.95% in Q4 2021 and bottomed at 67.5% in Q3 2021.